Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $39.50.

GMAB has been the subject of several research analyst reports. Truist Financial reissued a “buy” rating and issued a $48.00 price target (down previously from $49.00) on shares of Genmab A/S in a report on Thursday. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. HC Wainwright reiterated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Finally, Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday.

Genmab A/S Price Performance

Genmab A/S stock opened at $28.66 on Monday. The company’s 50 day simple moving average is $29.61 and its 200 day simple moving average is $24.49. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $33.65. The firm has a market capitalization of $18.40 billion, a price-to-earnings ratio of 12.20, a PEG ratio of 1.56 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 24.48%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. Jones Financial Companies Lllp lifted its position in Genmab A/S by 29.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after acquiring an additional 440 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the period. CWM LLC lifted its holdings in shares of Genmab A/S by 28.3% in the third quarter. CWM LLC now owns 2,306 shares of the company’s stock valued at $71,000 after purchasing an additional 509 shares in the last quarter. Captrust Financial Advisors lifted its holdings in shares of Genmab A/S by 2.4% in the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after purchasing an additional 526 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock worth $332,000 after buying an additional 532 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.